Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2014; 20(24): 7819-7829
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7819
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7819
Pancreatic biomarkers: Could they be the answer?
Angela Lamarca, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
Angela Lamarca, Jaime Feliu, Department of Medical Oncology, La Paz University Hospital, 28046 Madrid, Spain
Author contributions: Lamarca A and Feliu J performed manuscript writing and reviewing.
Correspondence to: Angela Lamarca, MD, PhD, Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom. angela.lamarca@christie.nhs.uk
Telephone: +44-16-14468106 Fax: +44-16-14463468
Received: October 29, 2013
Revised: December 11, 2013
Accepted: January 14, 2014
Published online: June 28, 2014
Revised: December 11, 2013
Accepted: January 14, 2014
Published online: June 28, 2014
Core Tip
Core tip: Implementing the clinicopathological information with molecular characteristics for treatment individualization in pancreatic cancer seems to be one of the keys to improving survival and response to treatment. The development of new biomarkers and a better definition of the current ones are radically important. This review will summarize the most important biomarkers defined for pancreatic adenocarcinoma and their current development status.